Why GlaxoSmithKline plc Might Be Worth £20!

Buying GlaxoSmithKline plc (LON: GSK) now could lead to a 48% capital gain

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

A key reason for the FTSE 100‘s disappointing performance versus other major indices is the lack of share price growth from some of its biggest constituents. This is crucial in a market-weighted index, where the bigger the company the more significant its impact on the index price level.

One example of such a stock is GlaxoSmithKline (LSE: GSK). It is currently the sixth biggest company by market capitalisation in the index and its price has fallen by 9% in the last year, thereby dragging the wider FTSE 100 down. And, with its performance in prior years also having been poor and heavily affected by bribery allegations and generic competition on key products, many investors will understandably be feeling rather downbeat regarding its future prospects.

However, GlaxoSmithKline could realistically rise to £20 over the medium to long term. That would equate to a capital gain of 48% from its current price of £13.50 and a key reason for this is its dividend appeal. With the Bank of England being at pains to point out that interest rate rises will be slow, steady and may not start until more than halfway through next year, GlaxoSmithKline’s 6%+ yield has high appeal.

In fact, with the market being of the view that the base rate will stand at just 1.3% by the end of 2018, 6%+ yields are likely to command huge demand in future years. And, if GlaxoSmithKline were to trade at £20, its yield would fall to 4%, which is in-line with the yield of the wider index.

Furthermore, with the uncertainty that the world currently faces (both politically and economically), more stable and resilient stocks such as GlaxoSmithKline could become en vogue. That’s especially the case since the pharmaceutical sector is less positively correlated with the performance of the wider economy and so can provide higher returns during less favourable periods for cyclical stocks.

In addition, GlaxoSmithKline has an excellent pipeline of new drugs which are likely to propel its earnings higher in future years. For example, its ViiV Healthcare divisions is among its most exciting prospects and this should be an engine of growth for the business, while cost cutting and efficiencies are also set to make a positive impact on the company’s bottom line.

Evidence of their impact can be seen in 2016’s forecast earnings numbers, with GlaxoSmithKline expected to increase its bottom line by 11%. And, looking further ahead, the potent mix of a strong pipeline of new treatments and improved efficiencies could lead to a similar rate of growth in future years.

Despite this positive growth outlook, the company’s shares trade on a price to earnings (P/E) ratio of just 15.9. For a pharmaceutical major, this appears to be rather low and GlaxoSmithKline could easily demand a P/E ratio of over 17, particularly when its upbeat prospects are taken into account. This rating, plus three years of 11% earnings growth, would be sufficient to push the company’s share price to above £20, thereby providing its investors with a healthy return.

Clearly, GlaxoSmithKline is not without risk and, as with all pharmaceutical companies, pipelines can fail to yield the expected results. However, GlaxoSmithKline’s risk/reward ratio is highly enticing and, while it has disappointed in the past, its future performance looks set to make a positive contribution to the FTSE 100.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »